Unconventional T cell biologist and genome engineer. Previously @cardiffuni @nyuniversity @nygenome 🏳️🌈
New York, USA
Joined September 2020
- Tweets149
- Following299
- Followers490
- Likes425
Mat Legut, PhD retweeted
Excited to share a big milestone for OverT Bio—we’ve formed our Clinical Advisory Board.
Grateful to partner with an incredible group of leaders as we build scalable γδ CAR-T therapies for solid tumors.
businesswire.com/news/home/2…
Mat Legut, PhD retweeted
Come and join the extraordinary team of ALLOX and help us accelerate the discovery of more effective therapies!
👉allox.bio/careers
Our team in #Barcelona is expanding & we're #hiring 2 talented scientists to fill these exciting new positions: a Lead Scientist & a Research Associate.
Do u want to make a real difference in the future of applied high-throughput genetics and therapeutics? #PhdChat #ScienceJobs
Mat Legut, PhD retweeted
🎉Congratulations to the team at @OverT_Bio and its co-founders, @MatLegut and former CRI Tech Impact Award Grantee @nevillesanjana on the company's debut! Learn more in @endpts:
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Mat Legut, PhD retweeted
Congrats to @MatLegut & the entire @OverT_Bio team! Grateful for the opportunity to translate discoveries from our lab @nygenome & @nyuniversity into therapies for cancer patients.
Thrilled to be a part of this amazing team — onward and upward! 🚀
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Mat Legut, PhD retweeted
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Mat Legut, PhD retweeted
Big news!! I can finally officially announce that a few weeks ago, ALLOX @ALLOXbio was co-founded by the brilliant André Faure @aj4re , Pablo Baeza @pbcenturion , Ben Lehner @BenLehner , and myself, who will be stepping in as CEO of the company.
Mat Legut, PhD retweeted
Great effort from the team on this study published in Cell today! Hard work pays off - well done everyone 👏🏻
Exciting science - discovering new T-cell receptors for cancer immunotherapies 🔬
#cancerimmunotherpies #cellscience #tcells
cell.com/cell/fulltext/S0092…
Mat Legut, PhD retweeted
For anyone interested in our work and our team - we would greatly appreciate extra votes in the following competition! Voting is open until the 4th July 🗳️🙏🏻🧬🧪
MolecularCloud | 2023 Distinguished Research Awards for Gene and Cell Therapy molecularcloud.org/researcha…
Mat Legut, PhD retweeted
I had some fun taking my #ScienceTwitter game to the next level with @WIRED 🐦🎮👨🔬 🙂
And several awesome CRISPR questions too!✂️🧬
Mat Legut, PhD retweeted
NEW content online! Multiomics-guided cellular immunotherapies dlvr.it/SmTtT9
Mat Legut, PhD retweeted
.@nevillesanjana and colleagues from NYU and @nygenome developed a genetic screening platform to identify genes that transform immune cells into more aggressive cancer fighters. Their promising study was published in @Nature. Vote for it in #statmadness: statnews.com/feature/stat-ma…
ALT NYU researchers working in a lab
Mat Legut, PhD retweeted
Congrats to our former postdoc @MatLegut whose work on engineered T cells is featured in the 2023 #STATMadness for the most innovative research! 🙌👨🔬🧬💊
In the first round, we are head-to-head with MIT. 🙂🦫 I know who I have going all the way in my bracket. Go team!!!
Get ready for #STATMadness! Voting starts tomorrow: trib.al/PqRV0fu
ALT A blue graphic with the STAT Madness logo reads "Which Institution Is The MVP Of Health And Medicine?"
Mat Legut, PhD retweeted
CaRPool-seq is out today @naturemethods. Excited to see how multimodal combinatorial perturbation screens in single cells will enable new discoveries. Many thanks for this great collab w/ @alexmenman, @nevillesanjana, @satijalab and other, powered by @cegs_ica.
CaRPool-seq from @satijalab, @nevillesanjana and colleagues makes use of the RNA-targeting CRISPR-Cas13d system to perform combinatorial perturbations in single-cell screens. nature.com/articles/s41592-0…
Mat Legut, PhD retweeted
Our new article is now online! @AvaKaranjia
pubs.acs.org/doi/10.1021/acs…
We used PAM-expanded dCas9s developed by our collaborators @nevillesanjana & @BKleinstiver to expand the bacterial CRISPR tools for gene regulation!
Shout out to Jesse and James who're not on twitter~~~
Mat Legut, PhD retweeted
The Queen died peacefully at Balmoral this afternoon.
The King and The Queen Consort will remain at Balmoral this evening and will return to London tomorrow.
Mat Legut, PhD retweeted
krb-sjobs.brassring.com/TGne…
We're recruiting a Research Assistant to work on this exciting collaborative project, apply above #Tcells #CancerImmunotherapy #ResearchJobs
xitter.cf/CancerGrand/status/153…
NexTGen will take on the solid tumours in children challenge & develop nextgen CAR T-cell therapies for children with #braintumours and #sarcomas
Congratulations Catherine Bollard (@ChildrensNatl) Martin Pule (@UCL) and the team, funded by @CR_UK, @theNCI and @TheMarkFdn
5/n
Mat Legut, PhD retweeted
@NucleateHQ's Activator is now OPEN for biotech company builders.
Accepting applications from academics worldwide. Bring your own idea or join a team.
apply.nucleate.xyz/
Mat Legut, PhD retweeted
In the latest issue! Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope dlvr.it/SW7qvF
Mat Legut, PhD retweeted
I was inspired by some Science Twitter debates about postdocs that occurred after AAI this year. So, I wrote it up in this month’s editorial for Immunology. Potentially spicy takes ahead, but that’s what you get with me! onlinelibrary.wiley.com/doi/…
Mat Legut, PhD retweeted
You can read our latest paper on Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope cell.com/cell/fulltext/S0092…
